

Yi Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6248672/publications.pdf>

Version: 2024-02-01

80
papers

3,408
citations

279778

23
h-index

168376

53
g-index

93
all docs

93
docs citations

93
times ranked

3827
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. <i>Lancet Public Health</i> , The, 2020, 5, e661-e671.	10.0	573
2	Dementia in China: epidemiology, clinical management, and research advances. <i>Lancet Neurology</i> , The, 2020, 19, 81-92.	10.2	412
3	The cost of Alzheimer's disease in China and re-estimation of costs worldwide. <i>Alzheimer's and Dementia</i> , 2018, 14, 483-491.	0.8	404
4	The prevalence of dementia in urban and rural areas of China. <i>Alzheimer's and Dementia</i> , 2014, 10, 1-9.	0.8	322
5	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.8	310
6	The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. <i>Alzheimer's and Dementia</i> , 2014, 10, 439-447.	0.8	144
7	Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage. <i>Alzheimer's and Dementia</i> , 2021, 17, 49-60.	0.8	122
8	TREM2, microglia, and Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2021, 195, 111438.	4.6	74
9	Toward a theory-based specification of non-pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations. <i>Alzheimer's and Dementia</i> , 2021, 17, 255-270.	0.8	55
10	<i>PSEN1</i> , <i>PSEN2</i> , and <i>APP</i> mutations in 404 Chinese pedigrees with familial Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 178-191.	0.8	53
11	Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia. <i>Journal of the Neurological Sciences</i> , 2016, 370, 82-87.	0.6	48
12	The effects of 7-week cognitive training in patients with vascular cognitive impairment, no dementia (the CogVACCINE study): A randomized controlled trial. <i>Alzheimer's and Dementia</i> , 2019, 15, 605-614.	0.8	47
13	White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 47.	3.4	46
14	B vitamins and prevention of cognitive decline and incident dementia: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2022, 80, 931-949.	5.8	41
15	Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China. <i>Alzheimer's and Dementia</i> , 2016, 12, 446-453.	0.8	37
16	TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. <i>Molecular Neurodegeneration</i> , 2022, 17, .	10.8	36
17	Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA Research Framework. <i>Alzheimer's and Dementia</i> , 2018, 14, 532-534.	0.8	33
18	Sex Differences in Neuropsychiatric Symptoms of Alzheimer's Disease: The Modifying Effect of Apolipoprotein E4 Status. <i>Behavioural Neurology</i> , 2015, 2015, 1-6.	2.1	32

#	ARTICLE	IF	CITATIONS
19	The <i>APOE ε4</i> exerts differential effects on familial and other subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 1613-1623.	0.8	30
20	Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. <i>Brain</i> , 2021, 144, 924-937.	7.6	30
21	Efficacy and safety of the compound Chinese medicine <i>SaiLuoTong</i> in vascular dementia: A randomized clinical trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 108-117.	3.7	29
22	Hashimoto's encephalopathy cases: Chinese experience. <i>BMC Neurology</i> , 2012, 12, 60.	1.8	27
23	A systems-based model of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 168-171.	0.8	26
24	Stage-Specific Gender Differences in Cognitive and Neuropsychiatric Manifestations of Vascular Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2012, 27, 433-438.	1.9	25
25	Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1495-1504.	2.6	25
26	Association between atherosclerosis and Alzheimer's disease: A systematic review and meta-analysis. <i>Brain and Behavior</i> , 2020, 10, e01601.	2.2	23
27	<i>AARS2</i> leukoencephalopathy: A new variant of mitochondrial encephalomyopathy. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e00582.	1.2	22
28	The microRNA-1908 up-regulation in the peripheral blood cells impairs amyloid clearance by targeting ApoE. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 980-986.	2.7	20
29	Hashimoto's encephalopathy mimicking spinocerebellar ataxia. <i>Journal of Neurology</i> , 2011, 258, 1705-1707.	3.6	18
30	Plasma Ceramides and Neuropsychiatric Symptoms of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1029-1035.	2.6	18
31	Polymorphism of HD and UCHL-1 genes in Huntington's disease. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1473-1477.	1.5	17
32	Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 592-597.	0.8	17
33	Consensus statement on the neurocognitive outcomes for early detection of mild cognitive impairment and Alzheimer dementia from the Chinese Neuropsychological Normative (CN-NORM) Project. <i>Journal of Global Health</i> , 2019, 9, 020320.	2.7	17
34	Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 14.	6.2	17
35	Differentiation of neuropsychological features between posterior cortical atrophy and early onset Alzheimer's disease. <i>BMC Neurology</i> , 2018, 18, 65.	1.8	16
36	Clinical characteristics of patients with paraneoplastic myelopathy. <i>Journal of Neuroimmunology</i> , 2019, 330, 136-142.	2.3	16

#	ARTICLE	IF	CITATIONS
37	Loss of microglial EED impairs synapse density, learning, and memory. <i>Molecular Psychiatry</i> , 2022, 27, 2999-3009.	7.9	16
38	Default mode network integrity changes contribute to cognitive deficits in subcortical vascular cognitive impairment, no dementia. <i>Brain Imaging and Behavior</i> , 2021, 15, 255-265.	2.1	14
39	A Novel PSEN1 K311R Mutation Discovered in Chinese Families with Late-Onset Alzheimer's Disease Affects Amyloid- β^2 Production and Tau Phosphorylation. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 613-623.	2.6	13
40	The efficacy of Cognitive training in patients with VAsCular Cognitive Impairment, No dEmentia (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	12
41	Gene mutations associated with early onset familial Alzheimer's disease in China: An overview and current status. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1443.	1.2	12
42	Two novel presenilin-1 mutations (I249L and P433S) in early onset Chinese Alzheimer's pedigrees and their functional characterization. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 264-269.	2.1	10
43	Rationale and Design of a Multicenter, Phase 2 Clinical Trial to Investigate the Efficacy of Traditional Chinese Medicine SaiLuoTong in Vascular Dementia. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2626-2634.	1.6	9
44	Reduce the burden of dementia now. <i>Alzheimer's and Dementia</i> , 2018, 14, 845-847.	0.8	9
45	A novel mutation in the CYP27A1 gene in a family with cerebrotendinous xanthomatosis. <i>International Journal of Neuroscience</i> , 2020, 130, 972-975.	1.6	9
46	White Matter Fractional Anisotropy Is a Superior Predictor for Cognitive Impairment Than Brain Volumes in Older Adults With Confluent White Matter Hyperintensities. <i>Frontiers in Psychiatry</i> , 2021, 12, 633811.	2.6	9
47	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. <i>Journal of Nuclear Medicine</i> , 2022, 63, 981-985.	5.0	9
48	Safety and Efficacy of Donepezil 10mg/day in Patients with Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 199-211.	2.6	8
49	TRanscranial AlterNating current Stimulation FOR patients with Mild Alzheimer's Disease (TRANSFORM-AD study): Protocol for a randomized controlled clinical trial. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12005.	3.7	8
50	Cognitive profiles in adult-onset neuronal intranuclear inclusion disease: a case series from the memory clinic. <i>Neurological Sciences</i> , 2021, 42, 2487-2495.	1.9	8
51	The Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	8
52	New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia. <i>Alzheimer's and Dementia</i> , 2018, 14, 703-706.	0.8	6
53	Binaural processing deficit and cognitive impairment in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1085-1099.	0.8	6
54	Oltipraz attenuates the progression of heart failure in rats through inhibiting oxidative stress and inflammatory response. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 8918-8923.	0.7	6

#	ARTICLE	IF	CITATIONS
55	Lipid Metabolism in the Development and Progression of Vascular Cognitive Impairment: A Systematic Review. <i>Frontiers in Neurology</i> , 2021, 12, 709134.	2.4	6
56	Mercury Poisoning Presenting as Sporadic Creutzfeldtâ€“Jakob Disease: A Case Report. <i>Annals of Internal Medicine</i> , 2015, 162, 462-463.	3.9	5
57	Subdural Hematoma Associated with High Altitude. <i>Chinese Medical Journal</i> , 2015, 128, 407-408.	2.3	5
58	Neurology practice during the COVIDâ€“19 outbreak and postâ€“pandemic era: experiences and challenges. <i>European Journal of Neurology</i> , 2020, 27, e81-e83.	3.3	5
59	How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 917-919.	0.8	5
60	Plasma Clusterin as a Potential Biomarker for Alzheimerâ€“s Disease-A Systematic Review and Meta-analysis. <i>Current Alzheimer Research</i> , 2019, 16, 1018-1027.	1.4	5
61	A Bayesian perspective on Biogen's aducanumab trial. <i>Alzheimer's and Dementia</i> , 2022, 18, 2341-2351.	0.8	5
62	Autonomic dysfunction in a patient with X-linked adrenoleukodystrophy. <i>International Journal of Neuroscience</i> , 2018, 128, 783-784.	1.6	2
63	The Efficacy of COGNitive tRaining in patiEnts with Amnesic mild coGNitive impairment (COG-REAGENT): Protocol for a Multi-Center Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 779-787.	2.6	2
64	The synaptic marker neurogranin as a disease state biomarker in Alzheimerâ€“s disease: a systematic review and meta-analysis. <i>International Journal of Neuroscience</i> , 2021, , 1-9.	1.6	2
65	Altered brain activity mediates the relationship between white matter hyperintensity severity and cognition in older adults. <i>Brain Imaging and Behavior</i> , 2022, 16, 899-908.	2.1	2
66	Dementia and mild cognitive impairment in China: From the public health perspective. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
67	[O1â€“03â€“02]: FOUR NOVEL SUSCEPTIBILITY VARIANTS IDENTIFIED IN CHINESE ARE ASSOCIATED WITH SPORADIC ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P189.	0.8	1
68	The Effects of Normal Aging, Subjective Cognitive Decline, Mild Cognitive Impairment, or Alzheimerâ€“s Disease on Visual Search. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1639-1650.	2.6	1
69	P4â€“221: White Matter Damage in Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment No Dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, P1113.	0.8	0
70	P3â€“010: The COGâ€“Vaccine Study: Protocol for a Randomized Controlled Clinical Trial to Evaluate the Effect of Cognitive Training in Patients with Vascular Cognitive Impairment, No Dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, P821.	0.8	0
71	O2â€“11â€“05: ECONOMIC COST OF ALZHEIMER'S DISEASE IN CHINA: A CLUSTER RANDOMIZED OBSERVATIONAL STUDY. <i>Alzheimer's and Dementia</i> , 2016, 12, P255.	0.8	0
72	P1â€“447: CLINICAL AND NEUROIMAGING FEATURES OF THREE VARIANTS OF NONâ€“FAMILIAL EARLYâ€“ONSET ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P485.	0.8	0

#	ARTICLE	IF	CITATIONS
73	P1â€481: DEFAULT MODE NETWORK CONNECTIVITY CHANGE DETECTED BY DIFFUSION TENSOR IMAGING CONTRIBUTES TO COGNITIVE IMPAIRMENTS IN VASCULAR COGNITIVE IMPAIRMENT, NO DEMENTIA. Alzheimer's and Dementia, 2018, 14, P510.	0.8	0
74	P2â€467: GENE MUTATIONS ASSOCIATED WITH EARLYâ€ONSET FAMILIAL ALZHEIMER'S DISEASE IN CHINA: AN OVERVIEW AND CURRENT STATUS. Alzheimer's and Dementia, 2018, 14, P901.	0.8	0
75	P2â€025: THE EFFICACY OF COMPUTERIZED COGNITIVE TRAINING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT, NO DEMENTIA (THE COGâ€VACCINE STUDY): A RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2018, 14, P675.	0.8	0
76	Capgras Syndrome as the Core Manifestation of Early-Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, , 1-6.	2.6	0
77	Impairment of auditory integration in subjective cognitive decline, amnesic mild cognitive impairment, and Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
78	The synaptic marker neurogranin as a disease state biomarker in Alzheimerâ€™s disease: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.8	0
79	The influence of known pathogenic gene mutation and ApoEÎ¼4 on neuropsychological evaluation and imaging markers in preclinical stage of familial Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
80	B vitamins and prevention of cognitive decline and incident dementia: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.8	0